Clinical Trials
10 trialsNCT02876107 2026-04-15
Carboplatin and Paclitaxel With or Without Panitumumab in Treating Patients With Invasive Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01525966 2026-03-30
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Locally Advanced or Inflammatory Triple Negative Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT00295893 2025-09-25
Combination Chemotherapy With or Without Trastuzumab in Treating Patients With Stage II or Stage III Breast Cancer
City of Hope Medical Center
Phase 2 Active not recruiting
NCT05177796 2024-10-24
Panitumumab and Pembrolizumab in Combination With Neoadjuvant Chemotherapy for the Treatment of Stage III-IV Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Withdrawn
NCT01036087 2023-03-30
Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02682693 2021-02-02
GeparX
GBG Forschungs GmbH
Phase 2 Completed
NCT00096343 2018-12-04
Paclitaxel and Carboplatin in Treating Women Who Are Undergoing Surgery for Newly Diagnosed, Locally Advanced Breast Cancer
University of Alabama at Birmingham
Phase 2 Completed
NCT00182793 2017-02-23
Combination Chemotherapy With or Without Trastuzumab Followed By an Autologous Stem Cell Transplant and Radiation Therapy in Treating Patients With Stage III or Stage IV Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT00118053 2013-11-20
Trastuzumab, Docetaxel, and Carboplatin in Treating Women With Stage II, Stage III, or Inflammatory Breast Cancer
Rutgers, The State University of New Jersey
Phase 2 Terminated
NCT00005798 2012-10-26
CTC
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed